Bibliography Stephens FB, Constantin-Teodosiu D, Greenhaff PL (2007)
Cost-effectiveness analysis of four glucagon-like peptide-1 or glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists for the treatment of adult patients with overweight and obesity in china
Sources SURMOUNT-5 head-to-head results (Lilly): SURMOUNT-5 NEJM coverage (Pharmacy Times): LillyDirect Zepbound self-pay vials: Lilly Zepbound pricing: SURMOUNT-1, SURMOUNT-3, SURMOUNT-4 trial data: auto-rendered in the page citation panel Ready to try tirzepatide
With introductory pricing for new customers and ongoing rates well below retail, its worth checking whether you qualify before filling at a traditional pharmacy
Chiang CH, Jaroenlapnopparat A, Colak SC, et al
Discover more insights on GLP-1s by saving your virtual seat for ourwebinar with Bernstein Analyst, Alexia Howard